(Q37530899)

20 August 2017

1 reference

title

The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents (English)

1 reference

20 August 2017

0 references

Amani Makkouk

1

1 reference

PubMed ID

19555209

20 August 2017

Alexander M Abdelnoor

series ordinal

2

1 reference

20 August 2017

1 January 2009

1 reference

Immunopharmacology and Immunotoxicology

20 August 2017

1 reference

20 August 2017

31

1 reference

20 August 2017

331-338

1 reference

20 August 2017

3

1 reference

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

20 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Therapeutic targeting of pattern-recognition receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Immunobiology of Toll-like receptors: emerging trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Targeting toll-like receptors for drug development: a summary of commercial approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Toll-like receptors in inflammation, infection and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Toll-like receptors and immune regulation: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Toll-like receptors in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

TLR signaling by tumor and immune cells: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Innate tumor immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Inhibition of in vitro tumor cell proliferation by cytokines induced by combinations of TLR or TLR and TCR agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

TLR7 and TLR8 as targets in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08923970902802926

10.1080/08923970902802926

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19555209